GFM
BIOA

GF Fund Management’s BioAge Labs BIOA Stock Holding History

GF Fund Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9K Buy
797
+93
+13% +$1.79K ﹤0.01% 532
2025
Q4 		$9.31K Buy
+704
New +$6.24K ﹤0.01% 580

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GF Fund Management's BIOA Position: Q1 2026 in Review

GF Fund Management increased its BioAge Labs (BIOA) stake by 13% in Q1 2026, buying an estimated $1.79K and bringing the position to 797 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

GF Fund Management first reported a position in BIOA in Q4 2025 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • GF Fund Management held 797 shares of BioAge Labs worth $13.9K as of Q1 2026.
  • GF Fund Management bought 93 BioAge Labs shares in Q1 2026, an estimated $1.79K.
  • BioAge Labs made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #532 holding.
  • GF Fund Management first reported a position in BioAge Labs in Q4 2025 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.